News | April 29, 2009

Elevated Triglycerides Childhood Predictor of Future Cardiovascular Events

April 29, 2009 – Based on research presented at the 58th annual ACC Scientific Session, children with elevated levels of triglycerides may be at increased risk of cardiovascular disease (CVD) events in early adulthood, and as a result, pediatricians are encouraged to look at a child’s full lipid panel.

This finding is based on a 25 to 30 year follow-up study of 808 out of 1,756 subjects, first evaluated as school children between 1973 and 1976. Researchers restudied eligible participants to compare childhood and adult CVD risk factors in those who did and did not develop CVD in their 30s and 40s. Of these, 19 reported cardiovascular events as adults, the most common being heart attacks, angioplasties to re-open clogged coronary arteries, and bypass surgeries.

“Pediatric triglycerides are an exceptionally strong, independent predictor of early onset cardiovascular events,” said John Morrison, Ph.D., professor emeritus of Preventive Cardiology,Cincinnati Children’s Hospital. “Those who developed cardiovascular disease events tended to have higher levels of triglycerides and were more likely to be overweight or obese in childhood.”

Compared to the 789 CVD-free controls, participants who developed CVD had higher average childhood triglyceride (127 vs. 76 mg/dl, p

In multivariate analyses, those with a history of CVD were also significantly more likely to abuse tobacco, be overweight or obese (BMI 33.2 vs. 28.6, p =.0078), live with diabetes, and have elevated triglycerides (251 vs. 135 mg/dl, p =.0016) and blood sugar (122 vs. 90 mg/dl, p =.0001) as adults compared to the CVD-free group. These risk factor differences remained significant even after adjusting for adult age, sex and race. Normal triglyceride levels are less than 150 mg/dl.

Participants’ blood was drawn at hospitals in their area and sent overnight to Cincinnati Children’s Hospital. Comparisons of the original childhood data between participants and nonparticipants (those who were not followed) indicated that participants had higher BMI as children (p = 0.004). After adjusting for age, sex and BMI, differences in total cholesterol, LDL cholesterol, HDL cholesterol, and triglyceride levels between the participants and non-participants in childhood were not significant, indicating those who were followed did not differ from those who were not followed with respect to lipid profile.

Although there were few cases of CVD in this young study group, the data suggest pediatric triglycerides and obesity play a role in the development of early CVD.

"In the last decade, we have started to appreciate more the role of triglyceride-rich remnant particles in cardiovascular risk, and how they can accelerate the formation of lipid deposits in the arteries," Morrison said.

"While lowering LDL-cholesterol levels remains a primary therapeutic target, pediatric triglycerides and obesity, as well as smoking and early onset type 2 diabetes, remain serious risk factors for early CVD," said Samrat Yeramaneni, M.D., clinical research associate, Jewish Hospital Cholesterol Center. "Based on our findings, we encourage pediatricians and family practitioners to take notice of elevated levels of triglycerides, which are a part of standard lipid profiles, and screen for overweight and obesity as indicators of future risk of CVD and initiate early interventions."

The baseline and follow-up studies were funded by the National Heart Lung and Blood Institute of the National Institutes of Health.

For more information:

Related Content

FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
Overlay Init